ArticleInternational journal of general medicine2025
The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The present study aimed to explore the predictive value and prognosis of apolipoprotein A-I (ApoA-I) in chronic heart failure (CHF) patients. Methods: We recruited 4442 patients with CHF who were admitted to The First Affiliated Hospital of Xinjiang University Medical University with a period of ten years from July 2012, and the mean follow-up time was 22.75 months. The endpoints were defined as all-cause mortality (ACM), the patients divided into low and high ApoA-I groups according to the optimal cutoff value of the ROC curve from finally analyzed HF patients. Results: In the whole follow-up periods, multivariate Cox regression analysis showed that total CHF patients in low ApoA-I groups had significantly increased risk of ACM as compared with patients in the high ApoA-I group (hazard ratio [HR]=0.702, 95%confidence interval [CI]: 0.603-0.817, P <0.001). This trend was consistent in patients with heart failure with mid-range (HFmrEF) (HR = 0.443, 95% CI: 0.298-0.658, P <0.001) and heart failure with preserved ejection fraction (HFpEF) (HR = 0.704, 95% CI: 0.539-0.919, P = 0.010), but not in heart failure with reduced ejection fraction (HFrEF) (HR = 0.806, 95% CI: 0.582-1.116, P = 0.194). Conclusion: The Apolipoprotein A-I concentrations significantly associated with ACM of CHF especially in HFmrEF and HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.